HALO Halozyme Therapeutics, Inc.

13.46
0  0%
Previous Close 13.49
Open 13.48
Price To book 0.00
Market Cap 1.73B
Shares 128,198,000
Volume 766,177
Short Ratio 18.90
Av. Daily Volume 1,956,880

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA June 26, 2017.
Subcutaneous rituximab
Various blood cancers
Phase 1/2 trials to be initiated in 2017.
Tecentriq and PEGPH20
Pancreatic and gastric cancers
Phase 1/2 initiated July 2016
Eribulin In Combination With PEGPH20
High-Hyaluronan (HA) HER2-negative breast cancer
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 dosing initiated March 2016. Phase 2 data released January 5, 2017.
PEGPH20
Pancreatic cancer
Phase 1b enrolment resumed July 2016 under revised protocol
PEGPH20 in combination with KEYTRUDA
Non-small cell lung cancer (NSCLC)
Approved September 12, 2014.
HYQVIA
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 2 topline data released 1Q 2014
HTI-501
Celluoite

Latest News

  1. ETFs with exposure to Halozyme Therapeutics, Inc. : March 6, 2017
  2. HALOZYME THERAPEUTICS INC Financials
  3. Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
  4. 5 Small-Cap Biotech Stocks to Buy in March
  5. Edited Transcript of HALO earnings conference call or presentation 28-Feb-17 9:30pm GMT
  6. HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition
  7. HALOZYME THERAPEUTICS INC Files SEC form 10-K, Annual Report
  8. Halozyme Therapeutics reports 4Q loss
  9. Halozyme Therapeutics reports 4Q loss
  10. 4:10 pm Halozyme Therapeutics beats by $0.09, beats on revs; reaffirms FY17 revs guidance
  11. Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results
  12. Q4 2016 Halozyme Therapeutics Inc Earnings Release - After Market Close
  13. Why Halozyme Therapeutics (HALO) Might Surprise This Earnings Season
  14. Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
  15. MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20
  16. Why Halozyme Therapeutics, Inc. Jumped 15.6% in January
  17. Halozyme To Host Fourth Quarter 2016 Financial Results Conference Call
  18. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : January 27, 2017
  19. 5 Small-Cap Biotech Stocks to Buy in February
  20. ETFs with exposure to Halozyme Therapeutics, Inc. : January 17, 2017